KDR activation in astrocytic neoplasms

Cancer

Volumn 86, Issue 7, 1999, Pages 1335-1341

  Carroll, Rona S ^a   Zhang, Jianping ^a   Bello, Lorenzo ^a   Melnick, Michael B ^b   Maruyama, Taka ^c   Black, Peter McL ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CELL SIGNALING TECHNOLOGY   (United States)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Brain; Carcinoma; Vascular endothelial growth factor

Indexed keywords

PROTEIN TYROSINE KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; ASTROCYTOMA; ENDOTHELIUM CELL; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

ANTIBODIES; ASTROCYTOMA; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; FEMALE; GLIOBLASTOMA; HUMANS; LYMPHOKINES; MALE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN ISOFORMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033214180     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1335::AID-CNCR32>3.0.CO;2-Z     Document Type: Article

References (25)

1. Klagsbrun M, D'amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factors Rev 1996;7(3): 259-70.
2. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 1994; 4(3):207-18.
3. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77(2):362-72.
4. Folkman J, Klagsburn M. Angiogenic factors. Science 1987; 235:442-7.
5. Russell DS, Rubinstein LJ. Tumors of central neuroepithelial origin. In: Pathology of tumours of the nervous system. 5th ed. Baltimore: Williams and Wilkins, 1989:83-161.
6. Louis DN, Cavenee WK. Neoplasms of the central nervous system. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997:2013-22.
7. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359(6398):845-8.
8. Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994;59(4):520-9.
9. Epstein RJ, Druker BJ, Roberts TM, Stiles CD. Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc Natl Acad Sci USA 1992;89:10453-9.
10. Shamah SM, Alberta JA, Giannobile WV, Guha A, Kwon YK, Carroll RS, et al. Detection of activated platelet-derived growth factor receptors in human meningioma. Cancer Res 1997;57(18):4141-7.
11. Scheithauer BW, Burger PC, Kleihues P. Histological typing of tumours of the central nervous system. New York: Springer, 1993.
12. Waltenberger J, Clausson-Welch L, Siegbahn A, Shibuya M, Heldin C-H. Different transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-95.
13. Czernik AJ, Girault JA, Nairn AC, Chen J, Snyder G, Kebabian, J, et al. Production of phosphorylation state-specific antibodies. Methods Enzymol 1991;201:264-83.
14. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227: 680-5.
15. Leon SP, Zhu J, Black PM. Genetic aberrations in human brain tumors. Neurosurgery 1994;34(4):708-22.
16. Furnari FB, Huang HS, Cavenee WK. Molecular biology of malignant degeneration of astrocytoma. Pediatr Neurosurg 1996;24:41-9.
17. Plate KH, Mennel HD. Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol 1995;47(2-3):89-94.
18. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86: 353-64.
19. Cheng SY, Su-Huang HJ, Nagane M, Ji XD, Wang D, Shih CC-Y, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996;93:8502-7.
20. Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Upregulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993;53(23):5822-7.
21. Damert A, Machein M, Breier G, Fujita MQ, Hanahan D, Risau W, et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res 1997;57(17): 3860-4.
22. Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens BV, Lapiere CM. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 1997;57: 5590-7.
23. Kim KJ, Li B, Winer J, Armanin M, Gillet N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362:841-4.
24. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367(6463):576-9.
25. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996;56(7):1615-20.